Results 41 to 50 of about 92,873 (239)

European Standard Clinical Practice Guideline and EXPeRT Recommendations for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms in Children and Adolescents

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs) are extremely rare and clinically heterogeneous. Management has largely been extrapolated from adult practice. This European Standard Clinical Practice Guideline (ESCP), developed by the EXPeRT network in collaboration with adult NEN experts, provides (adult) evidence ...
Michaela Kuhlen, Calogero Virgone, Antje Redlich, Michael Abele, Ricardo Lopez‐Almaraz, Tal Ben‐Ami, Ewa Bien, Gianni Bisogno, Maja Mazic Cesen, Andrea Ferrari, Malgorzata A. Krawczyk, Yves Reguerre, Dominik T. Schneider, Ines B. Brecht, Charlotte Rigaud, Bilgehan Yalcin, Rainer Claus, Christian Vokuhl, Constantin Lapa, Jörg Fuchs, Segolene Hescot, Thomas Walter, Julien Hadoux, Daniel Orbach   +23 more
wiley   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

The challenges of managing glioblastoma multiforme in developing countries: a trade-off between cost and quality of care

Hematology/Oncology and Stem Cell Therapy, 2011
BACKGROUND AND OBJECTIVES: The management of glioblastoma multiforme (GBM) in developing countries is hindered by the paucity of clear protocols due in part to growing economic constraints and the lack of availability of expensive chemotherapeutic agents.
Ahmed Salem, Sameh A. Hashem, Abdulla Al-Rashdan, Najeeb Ezam, Ala’a Nour, Amer Alsharbaji, Maher Sughayer, Issa Mohamad, Maher Elyan, Ala’a Addas, Maysa Al-Hussaini, Abdelatif Almousa   +11 more
doaj   +1 more source

Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma. [PDF]

PLoS ONE, 2018
Glioblastoma multiforme (GBM) is a highly heterogeneous and aggressive brain tumor with a dismal prognosis. Development of resistance towards cytostatic drugs like the GBM standard drug temozolomide is a severe problem in GBM treatment.
Doreen William, Madlin Walther, Björn Schneider, Michael Linnebacher, Carl Friedrich Classen   +4 more
doaj   +1 more source

Synthesis and Quantitative Structure–Activity Relationship of Imidazotetrazine Prodrugs with Activity Independent of O6-Methylguanine-DNA-methyltransferase, DNA Mismatch Repair and p53. [PDF]

, 2013
The antitumor prodrug Temozolomide is compromised by its dependence for activity on DNA mismatch repair (MMR) and the repair of the chemosensitive DNA lesion, O6-methylguanine (O6-MeG), by O6-methylguanine-DNA-methyltransferase (EC 2.1.1.63, MGMT). Tumor
Arris C. E., Arrowsmith J., Barvaux V. A., Boberg F., Boyd M. R., Bunz F., Damera K., Darkes M. J. M., De K., Denny B. J., Dimitrios Pletsas, Dinca E. B., Elrashied A. E. Garelnabi, Garelnabi E. A. E., Hirose Y., Honnalli S. S., Judson P. L., Karran P., Karran P., Kotera M., Leteurtre F., Li Li, Liu L., McElhinney R. S., McGarrity J. F., Mladek A. C., Nishizuka S., Pletsas D., Richard T. Wheelhouse, Roger M. Phillips, Sarkaria J. N., Schmidt B. F., Schmiedekamp A., Shealy Y. F., Siddiqui A. A., Smith R. H., Stevens M. F. G., Svilar D., Wang Y., Wheelhouse R. T., Wheelhouse R. T., Zhang J., Zhang J.   +42 more
core   +1 more source

Inhibiting stearoyl‐CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response

FEBS Letters, EarlyView.
Bone metastasis in prostate cancer (PCa) patients is a clinical hurdle due to the poor understanding of the supportive bone microenvironment. Here, we identify stearoyl‐CoA desaturase (SCD) as a tumor‐promoting enzyme and potential therapeutic target in bone metastatic PCa.
Alexis Wilson, Mackenzie K Herroon, Shane Mecca, Laimar C Garmo, Jacob Lindquist, Shrila Rajendran, Steve M. Patrick, Izabela Podgorski   +7 more
wiley   +1 more source

Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. [PDF]

, 2015
The standard of care for newly diagnosed glioblastoma (GBM) is surgery, then radiotherapy (RT) with concurrent temozolomide (TMZ), followed by adjuvant TMZ. We hypothesized patients with low diffusivity measured using apparent diffusion coefficient (ADC)
Chang, Warren, Cloughesy, Timothy F, Ellingson, Benjamin M, Hardy, Anthony J, Harris, Robert J, Lai, Albert, Leu, Kevin, Mody, Reema R, Nghiemphu, Phioanh L, Pope, Whitney B   +9 more
core   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Gossypol Suppresses Growth of Temozolomide-Resistant Glioblastoma Tumor Spheres

Biomolecules, 2019
Temozolomide is the current first-line treatment for glioblastoma patients but, because many patients are resistant to it, there is an urgent need to develop antitumor agents to treat temozolomide-resistant glioblastoma.
Hee Yeon Kim, Byung Il Lee, Ji Hoon Jeon, Dong Keon Kim, Seok-Gu Kang, Jin-Kyoung Shim, Soo Youl Kim, Sang Won Kang, Hyonchol Jang   +8 more
doaj   +1 more source

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. [PDF]

, 2000
A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse.
Albright, RE, Brada, M, Bruner, J, Fink, K, Fredericks, R, Friedman, H, Glantz, M, Greenberg, H, Hohl, RJ, Levin, VA, Olson, J, Osoba, D, Phillips, P, Prados, MD, Rampling, R, Selker, RG, Shapiro, W, Spence, A, Vick, NA, Yue, N, Yung, WK, Zaknoen, S   +21 more
core